FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2329115331> ?p ?o ?g. }

• W2329115331 abstract "Background: Estrogens play a crucial role in breast carcinogenesis and progression. The third-generation aromatase inhibitors (AIs) have therefore become the first choice endocrine drugs for post-menopausal women with breast cancer, since they present greater efficacy when compared with tamoxifen. However, mode of action, side effects and tolerability are distinct compared to tamoxifen. In this study, we evaluated clinical side-effects, levels of gonadotropin, prolactin, progesterone and estradiol in postmenopausal women undergoing endocrine treatment with aromatase inhibitors. Materials and Methods: 128 postmenopausal patients undergoing endocrine therapy with aromatase inhibitors were included in the study. They completed the assessment at their regular 3-month check up. For the assessment of side-effects and symptom burden we used the FACT-B/+ES and the HADS. Blood samples were collected within the routine blood collection and measurement of follicle stimulation hormone (FSH), luteinizing hormone (LH), progesterone, estradiol and prolactin plasma levels were performed by Immunoassay. Data were analyzed using Spearman rank correlation. Results: We found a significant negative correlation of LH and FSH with body mass index (BMI) of postmenopausal breast cancer patients (LH r=- 0.281, p=0.014; FSH r=-0.250, p=0.029) receiving aromatase inhibitors. Analyses revealed a significant positive correlation for LH and FSH levels with subjectively experienced weight gain (LH r=0.499, p=0.008; FSH r=0.550, p=0.003), dyspareunia and vaginal dryness. Moreover, patients with a BMI ≥25 had significantly more gynaecological symptoms (dyspareunia p=0.008 and vaginal dryness p=0.026) than patients witha lower BMI. Progesterone was significantly associated with subjective weight gain (r=0.248, p=0.014). Prolactin significantly correlated with loss of sex drive (r=0.256, p=0.050), mood swings (r=0.239, p=0.050) and irritability (r=0.244, p=0.046). Conclusion: Our results reveal distinct endocrine changes among postmenopausal breast cancer patients undergoing endocrine treatment with AIs. These results confirm the central role of estrogens in the evolution of adverse events to aromatase inhibitors. The main observation in this study, however, was the correlation of BMI and levels of hormone influenced by estrogenic activity. LH and FSH which are under control of various estrogen metabolites, were significantly associated with the BMI and might therefore serve as surrogate marker of estrogenic activity in serum of breast cancer patients. Direct measurement of estradiol (E2) showed no correlation with BMI indicating the influence of various other estrogen metabolites on the secretion of gonadotropins. Analysis of serum estrogen receptor bioactivity in these patients is currently underway. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-11-10." @default.
• W2329115331 created "2016-06-24" @default.
• W2329115331 creator A5000811638 @default.
• W2329115331 creator A5022499341 @default.
• W2329115331 creator A5032861326 @default.
• W2329115331 creator A5034695241 @default.
• W2329115331 creator A5054775104 @default.
• W2329115331 creator A5064305101 @default.
• W2329115331 creator A5072120604 @default.
• W2329115331 creator A5079917470 @default.
• W2329115331 creator A5089652976 @default.
• W2329115331 date "2010-12-15" @default.
• W2329115331 modified "2023-09-27" @default.
• W2329115331 title "Abstract P5-11-10: Gonadotropins Plasma Levels Are Significantly Influenced by Body Mass Index in Postmenopausal Breast Cancer Patients Undergoing Endocrine Therapy with Aromatase Inhibitors: Is This a Surrogate Marker for Serum Estrogen Bioactivity?" @default.
• W2329115331 doi "https://doi.org/10.1158/0008-5472.sabcs10-p5-11-10" @default.
• W2329115331 hasPublicationYear "2010" @default.
• W2329115331 type Work @default.
• W2329115331 sameAs 2329115331 @default.
• W2329115331 citedByCount "0" @default.
• W2329115331 crossrefType "proceedings-article" @default.
• W2329115331 hasAuthorship W2329115331A5000811638 @default.
• W2329115331 hasAuthorship W2329115331A5022499341 @default.
• W2329115331 hasAuthorship W2329115331A5032861326 @default.
• W2329115331 hasAuthorship W2329115331A5034695241 @default.
• W2329115331 hasAuthorship W2329115331A5054775104 @default.
• W2329115331 hasAuthorship W2329115331A5064305101 @default.
• W2329115331 hasAuthorship W2329115331A5072120604 @default.
• W2329115331 hasAuthorship W2329115331A5079917470 @default.
• W2329115331 hasAuthorship W2329115331A5089652976 @default.
• W2329115331 hasConcept C121608353 @default.
• W2329115331 hasConcept C126322002 @default.
• W2329115331 hasConcept C134018914 @default.
• W2329115331 hasConcept C2776166826 @default.
• W2329115331 hasConcept C2776215463 @default.
• W2329115331 hasConcept C2777164284 @default.
• W2329115331 hasConcept C2777176818 @default.
• W2329115331 hasConcept C2778504769 @default.
• W2329115331 hasConcept C2778575703 @default.
• W2329115331 hasConcept C2779064019 @default.
• W2329115331 hasConcept C2779279165 @default.
• W2329115331 hasConcept C2780221984 @default.
• W2329115331 hasConcept C29456083 @default.
• W2329115331 hasConcept C46699223 @default.
• W2329115331 hasConcept C530470458 @default.
• W2329115331 hasConcept C71315377 @default.
• W2329115331 hasConcept C71924100 @default.
• W2329115331 hasConceptScore W2329115331C121608353 @default.
• W2329115331 hasConceptScore W2329115331C126322002 @default.
• W2329115331 hasConceptScore W2329115331C134018914 @default.
• W2329115331 hasConceptScore W2329115331C2776166826 @default.
• W2329115331 hasConceptScore W2329115331C2776215463 @default.
• W2329115331 hasConceptScore W2329115331C2777164284 @default.
• W2329115331 hasConceptScore W2329115331C2777176818 @default.
• W2329115331 hasConceptScore W2329115331C2778504769 @default.
• W2329115331 hasConceptScore W2329115331C2778575703 @default.
• W2329115331 hasConceptScore W2329115331C2779064019 @default.
• W2329115331 hasConceptScore W2329115331C2779279165 @default.
• W2329115331 hasConceptScore W2329115331C2780221984 @default.
• W2329115331 hasConceptScore W2329115331C29456083 @default.
• W2329115331 hasConceptScore W2329115331C46699223 @default.
• W2329115331 hasConceptScore W2329115331C530470458 @default.
• W2329115331 hasConceptScore W2329115331C71315377 @default.
• W2329115331 hasConceptScore W2329115331C71924100 @default.
• W2329115331 hasLocation W23291153311 @default.
• W2329115331 hasOpenAccess W2329115331 @default.
• W2329115331 hasPrimaryLocation W23291153311 @default.
• W2329115331 hasRelatedWork W1967411366 @default.
• W2329115331 hasRelatedWork W1988845670 @default.
• W2329115331 hasRelatedWork W1996046061 @default.
• W2329115331 hasRelatedWork W2016520112 @default.
• W2329115331 hasRelatedWork W2058808664 @default.
• W2329115331 hasRelatedWork W2061351013 @default.
• W2329115331 hasRelatedWork W2084654778 @default.
• W2329115331 hasRelatedWork W2111379968 @default.
• W2329115331 hasRelatedWork W2114340354 @default.
• W2329115331 hasRelatedWork W2131873929 @default.
• W2329115331 hasRelatedWork W2349230054 @default.
• W2329115331 hasRelatedWork W2355748188 @default.
• W2329115331 hasRelatedWork W2361880561 @default.
• W2329115331 hasRelatedWork W2370543503 @default.
• W2329115331 hasRelatedWork W2386876618 @default.
• W2329115331 hasRelatedWork W2461174897 @default.
• W2329115331 hasRelatedWork W2474747496 @default.
• W2329115331 hasRelatedWork W2586448756 @default.
• W2329115331 hasRelatedWork W2902866799 @default.
• W2329115331 hasRelatedWork W3199961703 @default.
• W2329115331 isParatext "false" @default.
• W2329115331 isRetracted "false" @default.
• W2329115331 magId "2329115331" @default.
• W2329115331 workType "article" @default.